Catalent, Inc. (NYSE:CTLT) Shares Sold by Texas Permanent School Fund Corp

Texas Permanent School Fund Corp reduced its stake in Catalent, Inc. (NYSE:CTLT) by 20.0% in the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 29,880 shares of the company’s stock after selling 7,472 shares during the period. Texas Permanent School Fund Corp’s holdings in Catalent were worth $1,680,000 as of its most recent SEC filing.

Other institutional investors have also recently added to or reduced their stakes in the company. Lindbrook Capital LLC grew its holdings in Catalent by 79.4% in the 1st quarter. Lindbrook Capital LLC now owns 470 shares of the company’s stock worth $27,000 after buying an additional 208 shares in the last quarter. Thurston Springer Miller Herd & Titak Inc. acquired a new position in shares of Catalent during the second quarter valued at approximately $42,000. Mather Group LLC. bought a new stake in Catalent during the first quarter worth approximately $52,000. Longfellow Investment Management Co. LLC lifted its position in Catalent by 45.7% in the second quarter. Longfellow Investment Management Co. LLC now owns 972 shares of the company’s stock worth $55,000 after purchasing an additional 305 shares during the period. Finally, Principal Securities Inc. bought a new position in Catalent during the 4th quarter valued at $56,000.

Catalent Stock Performance

Shares of Catalent stock opened at $60.30 on Thursday. The firm has a 50 day simple moving average of $59.39 and a 200 day simple moving average of $57.17. The company has a debt-to-equity ratio of 1.35, a current ratio of 2.52 and a quick ratio of 1.77. The firm has a market cap of $10.91 billion, a P/E ratio of -9.89, a P/E/G ratio of 1.88 and a beta of 1.15. Catalent, Inc. has a fifty-two week low of $31.80 and a fifty-two week high of $61.20.

Insider Activity at Catalent

In other Catalent news, CEO Alessandro Maselli sold 9,088 shares of the business’s stock in a transaction dated Monday, July 29th. The stock was sold at an average price of $58.76, for a total value of $534,010.88. Following the completion of the transaction, the chief executive officer now directly owns 177,521 shares of the company’s stock, valued at $10,431,133.96. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. In other Catalent news, insider Ricky Hopson sold 662 shares of the company’s stock in a transaction that occurred on Friday, August 2nd. The stock was sold at an average price of $59.56, for a total value of $39,428.72. Following the sale, the insider now owns 29,974 shares in the company, valued at $1,785,251.44. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, CEO Alessandro Maselli sold 9,088 shares of the firm’s stock in a transaction on Monday, July 29th. The shares were sold at an average price of $58.76, for a total value of $534,010.88. Following the sale, the chief executive officer now directly owns 177,521 shares of the company’s stock, valued at approximately $10,431,133.96. The disclosure for this sale can be found here. Over the last quarter, insiders sold 13,409 shares of company stock worth $782,923. 0.31% of the stock is owned by insiders.

Analysts Set New Price Targets

Several brokerages recently weighed in on CTLT. Barclays raised their target price on Catalent from $47.00 to $63.00 and gave the company an “equal weight” rating in a research note on Friday, June 28th. William Blair reissued a “market perform” rating on shares of Catalent in a research note on Tuesday, September 3rd. Royal Bank of Canada restated a “sector perform” rating and issued a $63.50 price target on shares of Catalent in a research report on Thursday, July 11th. Finally, StockNews.com initiated coverage on shares of Catalent in a report on Wednesday. They issued a “sell” rating for the company. One research analyst has rated the stock with a sell rating, six have assigned a hold rating and one has given a buy rating to the stock. According to MarketBeat.com, Catalent presently has a consensus rating of “Hold” and an average price target of $58.08.

Catalent Company Profile

Catalent, Inc, together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. It operates in two segments, Biologics, and Pharma and Consumer Health. The Biologics segment provides formulation, development, and manufacturing for biologic proteins, cell gene, and other nucleic acid therapies; pDNA, iPSCs, oncolytic viruses, and vaccines; formulation, development, and manufacturing for parenteral dose forms, including vials, prefilled syringes, and cartridges; and analytical development and testing services for large molecules.